Stopping GLP-1: what the evidence says, and how to prepare for it.

1. Why people stop, and why "stop" is not "fail"

Adults stop GLP-1 therapy for many reasons, and most of them are not about the medication being ineffective. Common reasons include:

• Cost or insurance coverage changing.
• Supply constraints on a specific molecule or dose.
• Side effects that did not resolve at a tolerable level.
• Pregnancy planning (most AOMs are contraindicated in pregnancy).
• A planned medical pause (surgery, another treatment).
• Reaching a target the patient and physician agree on.
• Personal preference, after a period of treatment.

In real-world cohorts, around half of adults starting a GLP-1 for obesity discontinue within the first year. For most, the discontinuation is not framed by the patient as "stopping a chronic-disease treatment"; it is framed as "I tried it, it was not for me." That framing matters, because it shapes what comes next. We unpack the persistence data in why half of GLP-1 patients stop in the first year.

Stopping a treatment for a chronic disease is a clinical decision with predictable consequences. It is not a personal failure, and it is not a verdict on the medication.

2. STEP-1 extension: the year after withdrawal

The STEP-1 trial randomised 1,961 adults with overweight or obesity (without diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks, with concurrent lifestyle support in both arms. Average weight loss on treatment was 14.9% on semaglutide vs 2.4% on placebo (Wilding et al., NEJM 2021).⁶ The pre-specified extension by Wilding and colleagues, published in Diabetes, Obesity and Metabolism in 2022, followed a subset of those participants for one year after stopping the medication and the lifestyle programme.¹

The result, in plain terms: by one year after withdrawal, participants had regained, on average, two-thirds of the weight they had lost. Cardiometabolic improvements (blood pressure, lipids, glycaemia, C-reactive protein) followed the weight back, partially or fully, depending on the parameter. Importantly, the regain was not the result of "lack of effort": the same lifestyle support continued during the off-drug year. The regain was biological. Appetite signals returned, and the metabolic adaptation that follows weight loss made it harder to maintain the new energy balance.

The takeaway is not "the medication does not work". The takeaway is "obesity is a chronic disease, and chronic diseases respond to continuous treatment".

3. STEP-4: continued vs withdrawn semaglutide

STEP-4, published by Rubino and colleagues in JAMA in 2021, was designed to test exactly the withdrawal question. After a 20-week run-in on semaglutide 2.4 mg (during which participants lost on average 10.6%), 803 adults were randomised either to continue semaglutide or to switch to placebo for the next 48 weeks, with concurrent lifestyle support in both arms.²

The continued group lost an additional 7.9% of body weight over those 48 weeks. The withdrawn group regained 6.9%. The gap between the two arms at week 68 was about 14 percentage points of body weight, a clinically and statistically significant difference. The cardiometabolic parameters tracked the weight: continued treatment maintained the gains, withdrawal eroded them. Side effect profile in the continued arm was consistent with prior trials, with no new safety signals.

STEP-4 is the single most useful trial for the question "what happens if I stop". It separates the effect of stopping from any other variable, and the answer is unambiguous: weight returns, not because of moral failure, but because the biological brake is no longer there.

4. SURMOUNT-4: tirzepatide, same direction

The picture is consistent across molecules. Aronne and colleagues, in SURMOUNT-4 (JAMA 2024), randomised 670 adults who had reached a stable dose of tirzepatide after a 36-week open-label run-in (during which they lost an average 20.9%), to either continue tirzepatide or switch to placebo for 52 additional weeks, with the same lifestyle support in both arms.³

The continued group lost an additional 5.5% of body weight. The withdrawn group regained 14.0%. The pattern is the same as STEP-4: the medication does not "wear off" in those who continue, but its effect is conditional on continued use, in the same way that an antihypertensive does not "fail" when you stop, but its effect ends.

For people who hope a few months of GLP-1 will produce a permanent reset of their weight set-point, the trial evidence does not currently support that hope. For people who want to know that continued treatment continues to work, the trial evidence supports that.

5. What happens to appetite after stopping

Beyond the trial-level numbers, patients describe a recognisable subjective experience after stopping a GLP-1:

• Within days to a few weeks, hunger signals become more insistent.
• Meal sizes that felt satisfying suddenly feel small.
• Cravings, especially for energy-dense foods, return.
• The "food noise" that many patients describe as quieted on treatment becomes louder again.

This is consistent with the pharmacology. GLP-1 receptor agonists have a half-life that allows a return to baseline appetite signalling within weeks of the last dose. The biological return of hunger is not a sign of weakness; it is the predictable result of removing an exogenous appetite modulator. We discuss the related question of weight plateaus and short-term rebound during ongoing treatment in GLP-1 plateau and rebound.

6. Before stopping: what to plan with your physician

If stopping is on the table, planned or forced by circumstance, the following conversations are useful before the last dose:

• The reason for stopping. Is it temporary (supply, surgery, pregnancy) or open-ended (cost, side effects, decision)? The plan changes accordingly.
• Tapering. There is no formal pharmacological need to taper a GLP-1, but some physicians prefer a step-down dose to soften the appetite return. Discuss whether this is appropriate in your case.
• Cardiometabolic monitoring. If you have type 2 diabetes, hypertension or dyslipidaemia, the parameters may shift after stopping. The SELECT trial showed that the cardiovascular benefit of semaglutide in adults with established cardiovascular disease and overweight or obesity (without diabetes) is observed under continued treatment, with a 20% reduction in major adverse cardiovascular events.⁴ Stopping may change the conversation with your cardiologist.
• Restart conditions. Define, in advance, what would trigger a restart. Without that, the restart conversation tends not to happen, even when it should.
• Weight regain expectation. Expect some regain; the trial literature is consistent. This expectation is not pessimism; it is preparation. It also protects you from interpreting biology as personal failure.
• Bring structured information. Side effects, dose history, weight pattern, what helped. We have a short checklist in preparing your next AOM consultation.

7. After stopping: the behavioural and physical scaffolding

After stopping, the question is no longer "how do I lose more weight"; it is "what scaffolding makes the post-treatment phase as healthy as possible, given that some regain is likely?"

Three pillars are supported by the literature:

• Resistance training. Lean mass loss during the on-drug phase is a known feature of GLP-1 therapy (we cover this in muscle, bone and the resistance-training conversation). After stopping, resistance training matters even more, because it protects basal metabolic rate, reduces sarcopenic risk, and softens the regain trajectory.
• Sleep and circadian rhythm. Short and irregular sleep is associated with increased appetite signalling (ghrelin up, leptin down). Sleep is not a wellness slogan; it is a biological lever, especially when the GLP-1 brake is no longer present.
• Mental load support. Stopping is often accompanied by a sense of letting go of a tool that worked, and sometimes by guilt or disappointment when the body regains. Naming this, in a peer community moderated by patient experts and within structured between-visit support, is part of the work. We discuss this in detail in the mental load of being on an AOM.

International obesity-care guidance, including NICE NG246 in the United Kingdom, frames obesity care as a long-term programme that does not end with a single intervention, and recommends ongoing follow-up, which is at least as relevant after stopping a pharmacological treatment as it is during it.⁵

8. Stopping is a clinical decision

The most important framing of this article: stopping a GLP-1 is a clinical decision with clinical consequences, and it is best made in conversation with a physician who knows your trajectory. It is not a moral statement, and it is not a verdict on the medication or on the principle of treating obesity as a chronic disease.

Some people stop and never restart, and live a healthy life with what they learned during treatment. Some stop and restart later, when circumstances change. Some stop and discover, painfully, that the regain is not something they want to live with, and that information is itself useful. None of these outcomes is a failure.

If you are considering stopping, or if you have already stopped, you do not have to figure this out alone. The first step is bringing it up with your physician. The second step, increasingly, is using a structured tool (a medical companion app, a peer community moderated by patient experts) to make sure the silence between visits is not where things go wrong.

References

1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID 35441470.
2. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224. PMID 33755728.
3. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. doi:10.1001/jama.2023.24945. PMID 38078870.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PMID 37952131.
5. National Institute for Health and Care Excellence. Overweight and obesity management. NICE guideline NG246. London: NICE; 2025 (last reviewed 8 January 2026). https://www.nice.org.uk/guidance/ng246.
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.